sinc
decemb
outbreak
coronaviru
diseas
wuhan
china
spread
throughout
world
februari
coronaviru
studi
group
csg
intern
committe
taxonomi
virus
ictv
offici
name
novel
coronaviru
caus
epidem
sever
acut
respiratori
syndrom
coronaviru
april
case
worldwid
patient
die
mortal
rate
approxim
coagul
dysfunct
one
major
caus
death
patient
sever
previou
studi
shown
patient
die
met
criteria
set
intern
societi
thrombosi
haemostasi
isth
diagnosi
dissemin
intravascular
coagul
dic
therefor
peopl
liber
armi
profession
committe
critic
care
medicin
chines
societi
thrombosi
hemostasi
gather
expert
epidem
frontlin
wuhan
establish
committe
reach
consensu
consensu
includ
overview
coagul
dysfunct
coagul
test
anticoagul
therapi
replac
therapi
support
therapi
prevent
recommend
use
provid
guidanc
relev
clinic
work
novel
coronavirus
belong
coronaviru
sar
virus
util
protein
bind
angiotensin
convert
enzym
ace
protein
cell
surfac
membran
order
enter
human
cell
howev
protein
trimer
structur
novel
coronaviru
like
bind
protein
cell
surfac
result
novel
coronaviru
protein
time
higher
affin
compar
sar
viru
main
target
novel
coronaviru
mainli
distribut
heart
lung
kidney
test
digest
tract
therefor
patholog
result
show
sarscov
detect
alveolar
type
ii
epitheli
cell
monocyt
digest
tract
epitheli
cell
distal
renal
tubulesepitheli
cell
skin
sweat
gland
cell
parathyroid
pituitari
eosinophil
adren
cortex
cell
gastric
pariet
cell
pancreat
acinar
cell
tracheal
serou
gland
cell
differ
sarscov
mainli
detect
alveolar
type
ii
epitheli
cell
pulmonari
macrophag
partli
hilar
lymph
node
spleen
test
coronaviru
extens
tissu
distribut
caus
high
number
proinflammatori
cytokin
releas
promot
system
inflammatori
respons
syndrom
sir
acceler
cell
death
lung
liver
heart
kidney
adren
parenchym
organ
ultim
lead
multipl
organ
dysfunct
syndrom
mod
inflammatori
reaction
occur
organ
bodi
microvascular
system
damag
lead
abnorm
activ
coagul
system
patholog
manifest
generalis
small
vessel
vascul
extens
microthrombosi
previou
studi
shown
abnorm
urokinas
pathway
caus
sarscov
induc
lung
injuri
suggest
interact
novel
coronaviru
coagul
fibrinolyt
system
complic
molecular
mechan
requir
studi
recommend
past
medic
histori
fulli
understood
patient
coagul
function
accur
evalu
sever
patient
epidemiolog
analysi
case
china
conduct
chines
center
diseas
control
demonstr
death
relat
age
year
underli
condit
hypertens
coronari
heart
diseas
diabet
etc
current
consensu
includ
patient
age
year
complic
sever
chronic
underli
diseas
hypertens
diabet
coronari
heart
diseas
malign
structur
lung
diseas
pulmonari
heart
diseas
immunosuppress
critic
ill
individu
patient
seriou
underli
condit
might
high
risk
coagul
dysfunct
therefor
obtain
detail
sever
patient
necessari
tabl
qualiti
coagul
factor
exogen
coagul
system
presenc
anticoagul
blood
evacul
endogen
coagul
system
statu
assess
activ
partial
thromboplastin
time
aptt
prolong
aptt
indic
abnorm
quantiti
qualiti
coagul
factor
endogen
coagul
system
presenc
anticoagul
substanc
blood
shorten
aptt
indic
hypercoagul
statu
aptt
also
use
determin
heparin
dosag
evalu
common
coagul
pathway
thrombin
time
tt
fibrinogen
prolong
tt
normal
fibrinogen
level
indic
presenc
anticoagul
substanc
blood
prolong
tt
decreas
fibrinogen
level
suggest
hypofibrinogenemia
evalu
fibrinolyt
system
ddimer
dd
fibrin
degrad
product
fdp
increas
dd
fdp
suggest
fibrinolyt
system
activ
platelet
plt
count
number
plt
decreas
risk
bleed
increas
number
plt
increas
plt
prone
adhes
aggreg
releas
reaction
increas
risk
platelet
thrombosi
retrospect
analysi
patient
conduct
wuhan
jinyintan
hospit
show
patient
show
elev
dd
show
reduc
aptt
show
extend
aptt
show
shorten
pt
show
extend
pt
professor
tang
expert
committe
conduct
retrospect
analysi
routin
coagul
paramet
patient
found
plasma
fdp
dd
nonsurvivor
significantli
higher
survivor
pt
aptt
significantli
prolong
retrospect
analysi
patient
professor
peng
also
confirm
ddimer
increas
admiss
previou
studi
evidenc
elev
dd
independ
risk
factor
acut
respiratori
distress
syndrom
ard
mortal
patient
recommend
isthcdcc
dic
score
recommend
diagnos
coagul
dysfunct
dic
secondari
syndrom
character
intravascular
coagul
due
local
damag
manifest
coagul
failur
intermedi
link
develop
multipl
organ
failur
mof
professor
tang
retrospect
analysi
patient
show
dic
occur
nonsurvivor
survivor
present
dic
base
mainli
diagnost
criteria
scientif
standard
committe
ssc
isth
paramet
dic
diagnost
score
system
includ
pt
plt
fibrinogen
dd
score
diagnos
overt
dic
diagnos
nonovert
dic
would
need
evalu
daili
tabl
thrombosi
hemostasi
group
chines
medic
associ
hematolog
branch
recommend
chines
dic
score
system
cdss
ad
primari
diseas
revis
diagnost
threshold
viscoelast
test
use
whole
blood
reflect
coagul
statu
patient
exist
coagul
dysfunct
fulli
accur
therefor
recommend
viscoelast
test
use
evalu
coagul
function
sever
patient
viscoelast
coagul
test
mainli
includ
thromboelastograph
teg
coagul
platelet
function
analyz
sonoclot
centuryclot
main
indic
teg
includ
rtime
coagul
factor
activ
angl
ktime
fibrinogen
function
platelet
function
fibrinolyt
function
main
indic
sonoclot
centuryclot
includ
act
indic
coagul
factor
function
cr
indic
fibrinogen
function
pf
indic
platelet
function
teg
sonoclotcenturyclot
accur
assess
overal
coagul
statu
patient
teg
sonoclotcenturyclot
show
good
correl
assess
coagul
factor
fibrinogen
plt
critic
ill
patient
moreov
sonoclotcenturyclot
show
sensit
monitor
coagul
factor
platelet
function
teg
great
advantag
monitor
fibrinolyt
function
sever
patient
thromboembol
diseas
like
hypercoagul
state
routin
coagul
assay
may
show
shorten
pt
aptt
patient
viscoelast
test
may
show
coagul
factor
platelet
hyperfunct
signific
increas
dd
also
indic
possibl
thrombosi
repres
thrombosi
event
deep
vein
thrombosi
pulmonari
embol
myocardi
infarct
cerebr
infarct
anticoagul
therapi
recommend
without
anticoagul
contraind
parenter
anticoagul
drug
prefer
choic
drug
dosag
depend
locat
sever
embol
recommend
sever
patient
coagul
dysfunct
anticoagul
therapi
use
unfraction
heparinlowmolecularweight
heparin
recommend
reduc
deplet
coagul
substrat
sever
patient
activ
coagul
pathway
inflammatori
cytokin
storm
caus
excess
consumpt
coagul
factor
platelet
moreov
excess
deplet
coagul
substrat
caus
coagul
dysfunct
lead
develop
dic
even
mof
order
reduc
coagul
substrat
deplet
expert
suggest
gener
patient
given
dose
low
molecular
heparin
daili
patient
dd
level
return
normal
fdp
gml
andor
dd
unfraction
heparin
iukg
per
hour
use
coagul
function
platelet
must
reevalu
hour
initi
heparin
treatment
research
conduct
retrospect
analysi
patient
discov
use
lowmolecularweight
heparin
lmwh
anticoagul
patient
dd
valu
greater
timescan
significantli
reduc
mortal
compar
receiv
lowmolecularweight
heparin
treatment
publish
howev
treatment
plan
current
requir
evid
sever
patient
coagul
dysfunct
unfraction
heparinlmwh
recommend
anticoagul
therapi
unfraction
heparin
advantag
short
halflif
conveni
monitor
process
fact
neutral
protamin
therefor
recommend
unfraction
heparin
first
choic
also
recommend
unfraction
heparin
administ
intraven
dosag
determin
accord
coagul
function
organ
function
sever
coagul
dysfunct
start
low
dose
u
use
laboratori
indic
guid
titrat
lmwh
easi
adjust
monitor
due
long
halflif
therefor
recommend
use
mild
moder
coagul
dysfunct
initi
dose
gener
recommend
given
mgkg
intraven
subcutan
dosag
monitor
accord
antixa
activ
target
rang
iuml
lmwh
metabol
kidney
therefor
patient
kidney
dysfunct
need
monitor
atiii
activ
sever
patient
maintain
otherwis
may
affect
effect
anticoagul
atiii
activ
reduc
increas
supplement
fresh
frozen
plasma
continu
renal
replac
therapi
crrt
anticoagul
method
divid
system
anticoagul
local
anticoagul
anticoagul
system
anticoagul
method
reduc
blood
coagul
use
anticoagul
drug
intraven
local
anticoagul
method
reduc
blood
coagul
extracorpor
circuit
without
affect
blood
coagul
bodi
circuit
anticoagul
goal
local
anticoagul
system
anticoagul
use
patient
anticoagul
goal
system
anticoagul
recommend
alter
coagul
statu
treatment
primari
diseas
avoid
increas
risk
bleed
dose
anticoagul
drug
need
adjust
accord
patient
coagul
statu
recommend
dose
unfraction
heparin
shown
tabl
blood
statu
patient
need
monitor
within
h
anticoagul
administr
monitor
regularli
depend
sever
condit
teg
heparinas
comparison
test
recommend
titrat
unfraction
heparin
dosag
rrh
ratio
good
method
titrat
dose
unfraction
heparin
accord
chang
aptt
teg
rtime
sonoclotcenturyclot
act
previou
base
valu
protamin
consid
case
sever
heparin
overdos
use
lowmolecularweight
heparin
repeat
bolu
continu
pump
recommend
repeat
bolu
initi
intraven
dose
iukg
taken
min
treatment
addit
intraven
dose
iukg
taken
everi
hour
addit
dose
gradual
reduc
treatment
period
goe
activ
plasma
antixa
monitor
maintain
iuml
lmwh
dose
adjust
base
result
lmwh
rate
continu
pump
also
need
adjust
base
measur
plasma
antixa
activ
recommend
topic
citrat
anticoagul
recommend
sever
patient
activ
bleed
requir
crrt
sever
patient
activ
bleed
requir
crrt
treat
local
citrat
anticoagul
avoid
aggrav
coagul
disord
trisodium
citrat
solut
continu
administ
filter
dose
time
blood
flow
rate
mlmin
citric
acid
concentr
filter
reach
mmoll
free
calcium
filter
maintain
mmoll
venou
free
calcium
mmoll
citric
acid
dose
adjust
depend
concentr
ioniz
calcium
concentr
filter
calcium
chlorid
calcium
glucon
solut
dose
adjust
depend
serum
ioniz
calcium
concentr
bodi
critic
ill
patient
heparin
commonli
use
anticoagul
ecmo
adjuv
also
increas
risk
bleed
bleed
sever
patient
coagul
dysfunct
common
surgic
incis
ecmo
intub
site
nose
airway
gastrointestin
bleed
also
occur
seriou
intracrani
bleed
therefor
sever
patient
coagul
dysfunct
need
increas
monitor
coagul
function
ecmo
adjuv
monitor
method
commonli
involv
activ
clot
time
act
aptt
act
maintain
andor
act
aptt
maintain
time
normal
upper
limit
teg
heparinas
comparison
test
also
applic
ecmo
anticoagul
monitor
detail
method
refer
recommend
antixa
activ
use
monitor
heparin
dose
recommend
xa
activ
maintain
iuml
ecmo
plu
crrt
treatment
anticoagul
strategi
monitor
similar
receiv
ecmo
heparininduc
thrombocytopenia
hit
diseas
caus
plateletactiv
antibodi
treatment
heparin
mainli
manifest
thrombocytopenia
well
venou
arteri
thrombosi
even
death
literatur
review
show
incid
hit
approxim
incid
higher
unfraction
heparin
use
lmwh
use
hit
mainli
caus
platelet
factor
heparin
complex
stimul
immun
cell
produc
complex
antibodi
ie
hit
antibodi
turn
lead
persist
platelet
activ
activ
coagul
pathway
platelet
thrombosi
fibrin
thrombu
sever
case
lead
decreas
platelet
count
basal
valu
andor
show
sign
arterioven
thrombosi
administr
heparin
score
hit
antibodi
use
diagnos
hit
score
valid
clinic
predict
tool
hit
compos
element
relat
degre
thrombocytopenia
time
thrombocytopenia
heparin
product
exposur
associ
thrombot
complic
concurr
presenc
potenti
etiolog
thrombocytopenia
score
classifi
low
likelihood
hit
moder
highli
possibl
diagnosi
essenti
confirm
score
hit
iggspecif
antibodi
posit
patient
high
likelihood
confirm
hit
use
heparin
discontinu
switch
nonheparin
anticoagul
argatroban
bivalirudin
argatroban
patient
allerg
heparin
hit
choos
argatroban
anticoagul
argatroban
direct
thrombin
inhibitor
metabol
liver
caus
signific
increas
tt
recommend
dose
start
intraven
argatroban
infus
dose
adjust
base
dynam
chang
aptt
teg
rtime
sonoclotcenturyclot
act
valu
patient
moder
liver
dysfunct
heart
failur
argatroban
initi
administ
intraven
infus
case
multipl
organ
dysfunct
argatroban
administ
intraven
infus
bivalirudin
effect
anticoagul
compon
hirudin
deriv
fragment
directli
specif
inhibit
thrombin
activ
effect
shortliv
halflif
min
revers
appli
patient
hit
suspect
hit
start
dose
mgkgh
adjust
depend
aptt
teg
rtime
dynam
chang
sonoclotcenturyclot
act
valu
recommend
goaldirect
replac
therapi
recommend
sever
patient
coagul
dysfunct
goaldirect
replac
therapi
recommend
sever
patient
coagul
dysfunct
involv
routin
coagul
indic
teg
paramet
sonoclotcenturyclot
indic
pt
aptt
prolong
time
teg
rtime
min
sonoclotcenturyclot
act
anticoagul
whole
blood
fresh
frozen
plasma
infus
mlkg
soon
possibl
infus
coagul
indic
dynam
monitor
determin
addit
infus
dose
excess
fluid
load
present
patient
coagul
factor
supplement
combin
prothrombin
complex
concentr
fibrinogen
gl
teg
function
fibrinogen
level
test
indic
ff
mm
sonoclot
centuryclot
cr
cryoprecipit
fibrinogen
mlkg
human
fibrinogen
mgkg
infus
coagul
indic
dynam
monitor
maintain
plasma
fibrinogen
least
gl
addit
infus
sever
patient
bleed
platelet
transfus
recommend
platelet
count
l
sever
patient
intend
undergo
lumbar
punctur
present
activ
bleed
platelet
transfus
recommend
platelet
count
l
sever
patient
undergo
ecmo
platelet
transfus
recommend
platelet
count
l
previou
studi
shown
use
platelet
count
indic
platelet
transfus
shown
improv
outcom
critic
ill
patient
howev
use
platelet
function
indic
guid
platelet
transfus
critic
ill
patient
thrombocytopenia
may
benefici
improv
outcom
patient
studi
shown
platelet
transfus
recommend
teg
mm
sonoclotcenturyclot
pf
patient
receiv
antiplatelet
therapi
platelet
transfus
recommend
case
persist
bleed
platelet
dysfunct
even
thrombocytopenia
platelet
transfus
amount
individu
take
account
patient
weight
spleen
function
deplet
factor
dose
gener
unit
apheresi
platelet
equival
dose
platelet
concentr
per
dose
unit
apheresi
platelet
may
transfus
case
sever
lifethreaten
bleed
infus
dose
evalu
adjust
accord
effect
goal
transfus
minimum
dose
requir
maintain
platelet
count
target
one
unit
platelet
transfus
theoret
increas
platelet
l
l
kg
adult
bleed
effect
stop
activ
replac
therapi
sever
patient
recombin
factor
vii
recommend
hemorrhag
effect
stop
activ
replac
therapi
hypocoagul
state
still
indic
coagul
monitor
recombin
factor
vii
rvii
use
order
effect
stop
bleed
follow
condit
must
met
use
rvii
acidosi
hypothermia
hypocalcemia
correct
hematocrit
platelet
count
l
fibrinogen
gl
initi
dose
rvii
depend
state
bleed
rvii
given
interv
hour
drug
discontinu
base
amount
bleed
coagul
test
result
recommend
sever
patient
coagul
dysfunct
experienc
liver
failur
plasma
exchang
recommend
sever
patient
hepat
encephalopathi
grade
ii
higher
follow
manifest
diagnos
acut
liver
failur
obviou
digest
symptom
anorexia
abdomin
distens
nausea
vomit
progress
jaundic
serum
total
bilirubin
time
normal
upper
limit
short
time
daili
increas
prothrombin
activ
inr
exclud
caus
progress
liver
shrinkag
sever
patient
coagul
dysfunct
experienc
liver
failur
artifici
liver
support
system
alss
recommend
plasma
exchang
wide
use
effect
treatment
alss
therapeut
pe
process
plasma
separ
blood
cell
centrifug
membran
separ
discard
replac
freshfrozen
plasma
largemolecularweight
substanc
includ
autoantibodi
immun
complex
cholesterol
bilirubin
drug
poison
remov
plasma
pe
time
coagul
factor
supplement
improv
coagul
statu
critic
ill
patient
previou
studi
confirm
septic
shock
patient
use
larg
dose
vasoact
drug
maintain
blood
pressur
earli
plasma
exchang
decreas
dosag
vasoact
drug
remov
inflammatori
cytokin
reduc
capillari
leakag
platelet
consumpt
plasma
suffici
pe
perform
combin
plasma
adsorpt
perfus
andor
hemofiltr
plasma
exchang
volum
l
bodi
mass
kg
plasma
defici
pe
perform
ml
plasma
plasma
unavail
less
ml
plasma
adsorpt
perfus
hemofiltr
combin
therapi
recommend
viscoelast
test
recommend
evalu
coagul
function
monitor
anticoagul
therapi
critic
ill
patient
liver
failur
recommend
sever
patient
coagul
dysfunct
heparin
flush
vascular
access
placement
avoid
sever
patient
often
insert
central
venou
cathet
cvc
treatment
cvc
use
monitor
hemodynam
statu
administr
parent
nutrit
drug
blood
product
perform
hemodialysi
sometim
invas
intraarteri
blood
pressur
monitor
perform
hemodynam
unstabl
patient
maintain
potenc
vasular
access
devic
repeat
heparin
flush
recommend
current
guidelin
howev
heparin
increas
clot
time
may
result
fatal
hemorrhag
dose
high
frequent
heparin
flush
also
affect
result
coagul
test
disturb
monitor
heparin
dosag
therefor
consensu
recommend
avoid
heparin
flush
vascular
access
placement
sever
patient
coagul
dysfunct
recommend
sever
patient
coagul
dysfunct
infus
dose
crystalloid
synthet
colloid
control
maintain
adequ
tissu
perfus
previou
studi
shown
sonoclot
use
detect
coagul
statu
healthi
peopl
input
l
normal
salin
succinyl
gelatin
normal
salin
caus
averag
cr
increas
averag
act
shorten
overal
tendenc
toward
hypercoagul
howev
succinyl
gelatin
lead
averag
cr
reduct
averag
peak
time
extens
overal
tendenc
toward
hypocoagul
fluid
volum
increas
coagul
dysfunct
exacerb
dilut
effect
addit
isovolumetr
dilut
result
signific
decreas
platelet
aggreg
therefor
sever
patient
coagul
dysfunct
strict
control
excess
infus
fluid
especi
synthet
colloid
extracorpor
life
support
ecl
refer
use
equip
vitro
partial
complet
replac
organ
function
provid
life
support
case
lifethreaten
organ
dysfunct
broad
sens
ecl
includ
ecmo
support
cardiopulmonari
function
rrt
support
renal
function
alss
support
liver
function
ecl
continu
contact
blood
extern
artifici
surfac
materi
lead
activ
coagul
system
balanc
coagul
anticoagul
affect
result
addit
deplet
platelet
coagul
factor
anticoagul
drug
prevent
coagul
circuit
may
also
affect
patient
coagul
state
increas
risk
bleedinginduc
thrombocytopenia
induc
hit
guru
et
al
report
thrombocytopenia
occur
critic
ill
patient
plan
receiv
crrt
thrombocytopenia
occur
anoth
patient
crrt
patient
crrt
use
heparin
anticoagul
signific
platelet
declin
patient
without
crrt
use
heparin
anticoagul
score
indic
patient
meet
diagnost
criteria
hit
yet
posit
antibodi
rate
significantli
high
choi
et
al
report
rate
thrombocytopenia
patient
receiv
ecmo
high
vaecmo
like
vvecmo
caus
thrombocytopenia
platelet
consumpt
caus
membran
oxygen
induc
vwf
aggreg
incid
hit
reach
ecmo
patient
show
posit
antibodi
treat
ecmo
diagnosi
hit
need
consid
ecmo
circuit
frequent
abnorm
platelet
progress
decreas
high
level
specif
igg
antibodi
therefor
ecl
necessari
comprehens
assess
coagul
function
properli
select
anticoagul
strategi
posit
control
factor
coagul
dysfunct
specif
target
follow
platelet
count
l
prolong
pt
less
fibrinogen
gl
atiii
activ
atiii
monitor
larger
dose
unfraction
heparin
given
achiev
anticoagul
effect
atiii
defici
consid
fresh
frozen
plasma
given
signific
coagul
dysfunct
activ
bleed
occur
ecl
anticoagul
therapi
stop
necessari
